Pembrolizumab + carboplatin + paclitaxel (squamous NSCLC, first line)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PEMBROLIZUMAB` `DRUG-CARBOPLATIN` `DRUG-PACLITAXEL`

ID	`REG-PEMBRO-CARBO-PACLITAXEL-NSCLC-SQ`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-KEYNOTE-407-PAZ-ARES-2018` `SRC-KEYTRUDA-USPI-2026`

Notes

KEYNOTE-407 trial schedule. Paclitaxel and nab-paclitaxel are alternatives and must not be combined. No pemetrexed or pemetrexed maintenance. Selection and dose changes require clinician review; no current Ukrainian registration or reimbursement claim is made.

Used By

Indication

IND-NSCLC-SQ-PEMBRO-CARBO-PACLITAXEL-1L - IND-NSCLC-SQ-PEMBRO-CARBO-PACLITAXEL-1L